Triple-negative breast cancer drug breakthrough
A research team based in St Vincent’s University Hospital and University College Dublin hopes that the drug, APR-246, can prevent the growth of triple-negative breast cancer cells.
Each year, more than 250 people are diagnosed with triple-negative breast cancer. It is often aggressive, difficult to treat, and tends to be more common in younger women.
